| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.05 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.093 | 0.05 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | 0.09 | 0.06 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.068 | 0.06 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.068 | 0.06 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | 0.094 | 0.06 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.06 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.1 | 0.06 |
| mRNA | Mdivi-1 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.06 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.072 | 0.06 |